Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma | BSE | Healthcare | Pharmaceuticals | ₹4.17T | 36.2x | 1.28 | ₹1,730.35 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Sun Pharma | NSE | Healthcare | Pharmaceuticals | ₹4.17T | 36.2x | 1.28 | ₹1,730.85 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Divi's Labs | BSE | Healthcare | Pharmaceuticals | ₹1.58T | 76.5x | 1.6 | ₹5,955.30 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Divi's Labs | NSE | Healthcare | Pharmaceuticals | ₹1.58T | 76.5x | 1.6 | ₹5,946.10 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Cipla | BSE | Healthcare | Pharmaceuticals | ₹1.18T | 23.6x | 0.69 | ₹1,456.90 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Cipla | NSE | Healthcare | Pharmaceuticals | ₹1.18T | 23.6x | 0.69 | ₹1,459.65 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Max Healthcare Institute | NSE | Healthcare | Healthcare Providers & Services | ₹1.11T | 103x | -22.14 | ₹1,071.45 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.8% Upside | Upgrade to Pro+ | |
Max Healthcare Institute | BSE | Healthcare | Healthcare Providers & Services | ₹1.11T | 103x | -22.14 | ₹1,072.05 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.7% Upside | Upgrade to Pro+ | |
Torrent Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.08T | 58x | 2.41 | ₹3,197.40 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Torrent Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.08T | 58x | 2.41 | ₹3,188.05 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Mankind Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.83 | ₹2,480 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Mankind Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.83 | ₹2,478 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | BSE | Healthcare | Pharmaceuticals | ₹1.02T | 18.9x | 7.2 | ₹1,221.65 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | NSE | Healthcare | Pharmaceuticals | ₹1.02T | 18.9x | 7.2 | ₹1,219.15 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Lupin | NSE | Healthcare | Pharmaceuticals | ₹992.25B | 37.5x | 0.39 | ₹2,168.55 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.2% Upside | Upgrade to Pro+ | |
Lupin | BSE | Healthcare | Pharmaceuticals | ₹992.25B | 37.5x | 0.39 | ₹2,169.15 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Apollo Hospitals | NSE | Healthcare | Healthcare Providers & Services | ₹973.56B | 80.8x | 1.15 | ₹6,758.15 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.1% Upside | Upgrade to Pro+ | |
Apollo Hospitals | BSE | Healthcare | Healthcare Providers & Services | ₹973.56B | 80.8x | 1.15 | ₹6,736.15 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | NSE | Healthcare | Pharmaceuticals | ₹972.78B | 21.4x | 0.41 | ₹964.25 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | BSE | Healthcare | Pharmaceuticals | ₹970.11B | 21.3x | 0.41 | ₹962.85 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | BSE | Healthcare | Pharmaceuticals | ₹684.42B | 19.6x | 0.74 | ₹1,177.20 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.1% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | NSE | Healthcare | Pharmaceuticals | ₹684.42B | 19.6x | 0.74 | ₹1,174.50 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32% Upside | Upgrade to Pro+ | |
Abbott India | BSE | Healthcare | Pharmaceuticals | ₹631.87B | 47.1x | 2.88 | ₹29,750 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Abbott India | NSE | Healthcare | Pharmaceuticals | ₹631.87B | 47.1x | 2.88 | ₹29,695.55 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd | NSE | Healthcare | Pharmaceuticals | ₹574.20B | 26.7x | 0.78 | ₹4,800 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd BO | BSE | Healthcare | Pharmaceuticals | ₹574.20B | 26.7x | 0.78 | ₹4,815.60 | -6.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Fortis Healthcare | NSE | Healthcare | Healthcare Providers & Services | ₹473.92B | 61.4x | 3.76 | ₹626.80 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Fortis Healthcare | BSE | Healthcare | Healthcare Providers & Services | ₹473.92B | 61.4x | 3.76 | ₹625 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Biocon | NSE | Healthcare | Biotechnology & Medical Research | ₹452.15B | 56.1x | -1.74 | ₹377.20 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.4% Upside | Upgrade to Pro+ | |
Biocon | BSE | Healthcare | Biotechnology & Medical Research | ₹451.08B | 56.1x | -1.74 | ₹376.55 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.5% Upside | Upgrade to Pro+ | |
Glenmark Pharma | NSE | Healthcare | Pharmaceuticals | ₹428.31B | -48.9x | 0.05 | ₹1,516.90 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Glenmark Pharma | BSE | Healthcare | Pharmaceuticals | ₹428.31B | -48.9x | 0.05 | ₹1,517.55 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Ipca Laboratories | BSE | Healthcare | Pharmaceuticals | ₹367.95B | 55.6x | 1.69 | ₹1,446.95 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Ipca Laboratories | NSE | Healthcare | Pharmaceuticals | ₹367.85B | 55.6x | 1.69 | ₹1,447.60 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | NSE | Healthcare | Pharmaceuticals | ₹363.79B | 53.8x | 8.9 | ₹2,146.75 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | BSE | Healthcare | Pharmaceuticals | ₹363.79B | 53.8x | 8.9 | ₹2,147.50 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Laurus Labs | NSE | Healthcare | Pharmaceuticals | ₹339.08B | 168.3x | 26.1 | ₹626.50 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Laurus Labs | BSE | Healthcare | Pharmaceuticals | ₹339.08B | 168.3x | 26.1 | ₹625.45 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Ajanta Pharma Ltd | NSE | Healthcare | Pharmaceuticals | ₹324.62B | 36.4x | 1.62 | ₹2,599.15 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Healthcare | Pharmaceuticals | ₹324.62B | 36.4x | 1.62 | ₹2,612.95 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.1% Upside | Upgrade to Pro+ | |
Global Health | NSE | Healthcare | Healthcare Providers & Services | ₹313.92B | 61.1x | 5.07 | ₹1,132.85 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
Global Health | BSE | Healthcare | Healthcare Providers & Services | ₹313.92B | 61.1x | 5.07 | ₹1,134.45 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Piramal Pharma | NSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.73 | ₹221.50 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Piramal Pharma | BSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.73 | ₹221.55 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Syngene International Ltd | NSE | Healthcare | Biotechnology & Medical Research | ₹295.34B | 58.8x | ₹736.10 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | ||
Syngene International Ltd BO | BSE | Healthcare | Biotechnology & Medical Research | ₹295.04B | 58.8x | ₹733.80 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | ||
Suven Pharma | BSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.77 | ₹1,114.65 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.2% Upside | Upgrade to Pro+ | |
Suven Pharma | NSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.77 | ₹1,123.90 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Narayana Hrudayalaya | NSE | Healthcare | Healthcare Providers & Services | ₹283.58B | 36.4x | 6.5 | ₹1,393.15 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.2% Upside | Upgrade to Pro+ | |
Narayana Hrudayalaya | BSE | Healthcare | Healthcare Providers & Services | ₹283.58B | 36.4x | 6.5 | ₹1,397.05 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.2% Upside | Upgrade to Pro+ |